Search results for "Embolization"

showing 10 items of 156 documents

Transrenal ureteral occlusion: results and problems.

1994

Purpose The effectiveness of transrenal ureteral occlusion was evaluated. Patients and Methods Transrenal ureteral occlusions were performed in 83 ureters of 76 patients. Thirty-one ureters were occluded with use of tissue adhesive, which was secured in place with Gianturco coils in 21. Fifty-two ureters were occluded by means of silicone-filled, detachable latex balloons. Average follow-up was 3.6 months (range, 1 week to 38 months) for patients treated with the tissue adhesive and 7.9 months (range, 1 week to 61 months) for patients treated with the detachable balloons. Results Seventeen (55%) of the 31 ureters occluded with tissue adhesive and 36 (69%) of the 52 ureters occluded with det…

MaleAverage durationmedicine.medical_specialtyTime FactorsUrinary Fistulamedicine.medical_treatmentUreteropelvic junctionUrinary DiversionCatheterizationUreteral occlusionOcclusionmedicineHumansRadiology Nuclear Medicine and imagingEmbolizationAgedPelvic Neoplasmsbusiness.industryEmbolization TherapeuticSurgerymedicine.anatomical_structureFemaleTissue AdhesivesRadiologyUreterCardiology and Cardiovascular MedicinebusinessUrinary flowArteryFollow-Up StudiesJournal of vascular and interventional radiology : JVIR
researchProduct

Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.

2020

International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…

MaleHepatocellular carcinoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterologyEthiodized Oil0302 clinical medicineMESH: Infusions Intra-ArterialMESH: Liver NeoplasmsPharmacology (medical)EmbolizationMESH: Carcinoma HepatocellularComplete responseMESH: Treatment OutcomeMESH: AgedStandard treatmentLiver Neoplasms[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodol030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyIntra-arterial therapyCarcinoma HepatocellularAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesMESH: Ethiodized OilInternal medicinemedicineHumansInfusions Intra-ArterialIdarubicinContraindicationAgedMESH: Humansbusiness.industryMESH: Idarubicinmedicine.diseasedigestive system diseasesMESH: MaleRegimenMESH: Antineoplastic AgentsbusinessIdarubicin
researchProduct

Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.

2016

Abstract Purpose To perform an external validation of the Assessment for Retreatment with Transarterial Chemoembolization (ART) and α-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC), Child–Pugh, and response (ABCR) scores and to compare them in terms of prognostic power. Materials and Methods From 2000 to 2015, 871 patients with hepatocellular carcinoma underwent transarterial chemoembolization at a tertiary referral hospital, and 176 met all inclusion and exclusion criteria for both scores and were analyzed. Nineteen percent (n = 34) had BCLC stage A disease and 81% had stage B disease. Thirty-nine patients (22%) presented with elevated AFP levels. Overall survival was calculated. …

MaleOncologyCancer ResearchMultivariate analysisKaplan-Meier EstimateGastroenterologyTertiary Care Centers0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsMiddle AgedTreatment OutcomeOncologyBrier score030220 oncology & carcinogenesisPredictive value of testsHepatocellular carcinomaRetreatmentInclusion and exclusion criteriaFemale030211 gastroenterology & hepatologyalpha-FetoproteinsCardiology and Cardiovascular MedicineAlpha-fetoproteinLiver cancerAdultmedicine.medical_specialtyTreatment responseCarcinoma HepatocellularClinical Decision-MakingTertiary referral hospitalRisk AssessmentDecision Support TechniquesYoung Adult03 medical and health sciencesPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingAspartate AminotransferasesChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryPatient SelectionExternal validationReproducibility of ResultsRetrospective cohort studymedicine.diseaseConfidence intervalBCLC Stagedigestive system diseasesSurgerybusinessJournal of Clinical Oncology
researchProduct

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubici…

2016

Objectives The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD). Setting This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. Patients had to complete the EORTC QLQ-C30 HRQoL questionnaire at baseline and at days 15, 30 and 60 after TACE. Participants Patients aged ≥18 years with HCC unsuitable for curative treatments were evaluated for the study (N=21). Primary and secondary outcome measurements The …

MaleOncologyHealth-related Quality of LifePhases of clinical research[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of life1506FatigueAntibiotics AntineoplasticLiver NeoplasmsGeneral MedicineMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisHepatocellular carcinomaToxicityFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology030211 gastroenterology & hepatology1717medicine.drugmedicine.medical_specialtyCarcinoma HepatocellularMaximum Tolerated Dose1722Pain[SDV.CAN]Life Sciences [q-bio]/CancerPhase 1Disease-Free Survival03 medical and health sciencesInternal medicineCarcinomamedicineHumansIdarubicinChemoembolization TherapeuticAgedHealth-related Quality of ifeOncology clinical trialHealth related quality of lifebusiness.industryResearchlongitudinal analysis[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologyphase Imedicine.diseaseSurgeryTime to deteriorationMaximum tolerated doseQuality of LifeIdarubicinbusinessBMJ Open
researchProduct

Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma

2015

Background & aims To develop an individual prognostic calculator for patients with unresectable hepatocellular carcinoma (HCC) undergoing trans-arterial chemo-embolization (TACE). Methods Data from two prospective databases, regarding 361 patients who received TACE as first-line therapy (2000-2012), were reviewed in order to refine available prognostic tools and to develop a continuous individual web-based prognostic calculator. Patients with neoplastic portal vein invasion were excluded from the analysis. The model was built following a bootstrap resampling procedure aimed at identifying prognostic predictors and by carrying out a 10-fold cross-validation for accuracy assessment by means o…

MaleOncologymedicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaPrognosimedicine.medical_treatmentPortal veinEmbolization03 medical and health sciences0302 clinical medicineText miningSerum total bilirubinInternal medicineBiomarkers TumorHumansMedicineProspective StudiesEmbolizationChemoembolization TherapeuticAgedHepatologyPortal Veinbusiness.industryLiver NeoplasmsBilirubinMiddle AgedPrognosismedicine.diseaseSurvival AnalysisSurgeryClinical PracticeItaly030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisCohortTrans-arterial chemo-embolizationPrognostic modelFemale030211 gastroenterology & hepatologybusinessLiver International
researchProduct

Transgraft sac Embolization Combined with Graft Reinforcement for Refractory Mixed-Type Endoleak.

2018

International audience; An 80-year-old female underwent EVAR 4 years ago. She presented type II endoleak with sac expansion from 68 to 80 mm during 3-year follow-up after EVAR. Although she underwent translumbar percutaneous sac embolization, the AAA sac continued to enlarge, suggesting mixed-type endoleak including type I, II, and III. Transgraft direct sac angiography revealed endoleak cavity without demonstrable feeding vessel. Transgraft sac embolization using n-butyl cyanoacrylate and graft reinforcement was performed concurrently, without complications. The graft reinforcement consisted of graft extension for eliminating occult type I endoleak, and relining for eliminating occult type…

MaleReoperationmedicine.medical_specialtyTransgraft sac embolizationPercutaneousEndoleakmedicine.medical_treatmentMixed typeAortographyGraft reinforcement030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRefractoryMixed-type endoleaklawn-butyl cyanoacrylatemedicineHumansEVARRadiology Nuclear Medicine and imagingEmbolizationAged[SDV.IB] Life Sciences [q-bio]/BioengineeringAged 80 and overmedicine.diagnostic_testbusiness.industryN-butyl-cyanoacrylateEndovascular ProceduresEnbucrilateCombined Modality TherapyEmbolization Therapeutic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemSurgeryTreatment OutcomeCyanoacrylateAngiography[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleStentsCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedAortic Aneurysm AbdominalCardiovascular and interventional radiology
researchProduct

Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

2018

Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinoma (HCC) was recently proposed to optimize treatment allocation. The aim of this study was to assess the prognostic ability of that substaging proposal. Patients and methods This is a retrospective multicenter cohort study including patients with intermediate HCC treated with transarterial chemoembolization (TACE). Predictors of survival were identified using the Cox proportional regression model. Results 289 Barcelona Clinic Liver Cancer (BCLC) B patients were included. Medi…

MaleTime FactorsSpecialties of internal medicineKaplan-Meier EstimateGastroenterologyChemoembolization; Liver cancer; Radioembolization; Sorafenib; Staging system; Hepatology0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsGeneral MedicineMiddle AgedSorafenibTreatment OutcomeRC581-951Italy030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleChemoembolizationLiver cancerLiver cancerCohort studymedicine.drugSorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIARisk AssessmentDecision Support Techniques03 medical and health sciencesPredictive Value of TestsInternal medicineHumansChemoembolization TherapeuticRadioembolizationAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryProportional hazards modelRetrospective cohort studymedicine.diseaseStaging systemLog-rank testMultivariate Analysisbusiness
researchProduct

Clinical characteristics, treatment and outcome of 28 oral haemangiomas in paediatric patients

2010

Objective: To present a large series of oral haemangiomas in children, analyzing the clinical characteristics, treatment and outcome of oral haemangiomas in 28 children. Material and Methods: We conducted an observational retrospective study, reviewing medical records with clinical diagnosis of haemangioma between 1990 and 2006 at the Children?s Maxillofacial Surgery Service of the Hospital Universitario la Fe, Valencia. All patients with a clinical, radiographic, pathologically confirmed diagnosis of oral haemangioma were included. Results: The study included 28 patients (19 females and 9 males) with a mean age of 4.27 years (range 0-14 years). Nine were congenital haemangioma. The most fr…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRadiographyLesionHemangiomaTonguemedicineHumansEmbolizationChildGeneral DentistryRetrospective StudiesMouth neoplasmbusiness.industryMedical recordInfantRetrospective cohort study:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgerybody regionsTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyChild PreschoolUNESCO::CIENCIAS MÉDICASFemaleMouth NeoplasmsSurgerymedicine.symptomHemangiomabusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Left atrial thrombi despite anticoagulant and antiplatelet therapy

1994

To investigate risk factors for embolization in patients with echocardiographically detected left atrial thrombi and to evaluate thrombus development, we examined 29 patients with transesophageal and transthoracic echocardiography at two points during a follow-up of 18 months. We compared patients with a history of possible arterial embolization (n = 13) with those without (n = 16) in regard to age, gender, left atrial dilatation, localization of the thrombus in the left atrial cavity, spontaneous echo contrast, and atrial fibrillation. Eight patients were treated with aspirin, 20 with phenprocoumon. Only left atrial spontaneous contrast was associated with thromboembolism (10/15 patients w…

Malemedicine.medical_specialtyArterial embolismHeart Diseasesmedicine.drug_classmedicine.medical_treatmentEmbolismRisk FactorsInternal medicineAtrial FibrillationmedicineHumansMitral Valve StenosisHeart Atriacardiovascular diseasesEmbolizationThrombusAgedPeripheral Vascular DiseasesAspirinHeparinbusiness.industryArterial EmbolizationAnticoagulantThrombosisAtrial fibrillationGeneral MedicineIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEmbolismEchocardiographyPhenprocoumoncardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealDilatation PathologicFollow-Up Studiescirculatory and respiratory physiologyClinical Cardiology
researchProduct

Fistulous-type vein of Galen malformation phantom model for endovascular training and research.

2016

IntroductionVein of Galen malformation (VGM), a high-flow intracranial arteriovenous shunt, is among the most severe neurovascular diseases in childhood. In many cases untreated children die or survive only severely disabled. Endovascular embolization is the preferred treatment.ObjectiveTo develop a simple fistulous-type VGM phantom model for teaching and training of different endovascular treatment methods and to investigate new treatment options and devices.MethodsAn experimental in vitro pulsatile phantom model was developed imitating a high-flow fistulous-type VGM, which is typical, especially in the neonatal phase. Pressure measurements at different arterial sites were performed before…

Malemedicine.medical_specialtyBiomedical Researchmedicine.medical_treatmentHemodynamicsImaging phantom030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineFluoroscopyHumansEmbolizationChildmedicine.diagnostic_testbusiness.industryPhantoms ImagingVascular malformationEndovascular ProceduresArteriovenous malformationGeneral MedicineNeurovascular bundlemedicine.diseaseShunt (medical)Child PreschoolArteriovenous FistulaVein of Galen MalformationsSurgeryFemaleNeurology (clinical)Radiologybusiness030217 neurology & neurosurgeryJournal of neurointerventional surgery
researchProduct